Integrated Manufacturing and Marketing Business Scheme Operated by 共創未来ファーマ

「In June 2026, we newly launched 3 products containing 3 generic pharmaceutical ingredients. We also continued to work toward a stable supply of high-quality, high-value-added pharmaceuticals by maintaining thorough quality control based on our proprietary verification system and planned production and procurement systems linked to demand forecasts.」

「In the pharmaceutical manufacturing and sales business, 1 generic drug active ingredient and 3 products were newly launched in December 2025. The Company also worked to ensure a stable supply of high-quality, high-value-added pharmaceuticals through rigorous quality control based on its proprietary verification system and the establishment of planned production and procurement systems.」

「In December 2025, we newly launched 3 products containing 1 generic pharmaceutical ingredient. We also worked to ensure a stable supply of high-quality, high-value-added pharmaceuticals through thorough quality control based on our proprietary verification system and the establishment of planned production and procurement systems.」

「In the pharmaceutical manufacturing and marketing business, we worked to stably supply high-quality, high-value-added pharmaceuticals through rigorous quality control based on our proprietary testing system and the development of a planned production structure.」

「Generic drugs sold by Kyosai Mirai Pharma Co., Ltd. had been adopted by more than 1,000 large hospitals with 200 or more beds.」

「Generic drugs sold by Kyosai Mirai Pharma Co., Ltd. had been adopted by more than 1,000 large hospitals with 200 or more beds.」

「In addition, 1 generic drug active ingredient and 3 products were newly launched in June’s supplemental National Health Insurance drug price listing. As of the end of June 2023, generic drug products for sale totaled 87 active ingredients and 200 products.」

「In addition, the Company worked to expand its lineup, including the launch of 1 generic drug active ingredient and 2 products in December 2022. As of the end of December 2022, generic drug products for sale totaled 89 active ingredients and 208 products.」

「In addition, the Company worked to expand its lineup, including obtaining marketing approval for 1 generic drug active ingredient and 2 products in August. As of the end of September 2022, generic drug products for sale totaled 88 active ingredients and 206 products.」

「In addition, 2 generic drug active ingredients and 3 products were newly launched in June’s supplemental National Health Insurance drug price listing. As of the end of June 2022, generic drug products for sale totaled 88 active ingredients and 206 products.」

「In the pharmaceutical manufacturing and sales business, the Company worked to ensure a stable supply of high-quality, high-value-added pharmaceuticals by strictly monitoring product quality based on its proprietary verification system, while continuing to expand its product lineup, including the launch of 8 generic drug active ingredients and 15 products during the fiscal year. As of the end of March 2022, products for sale totaled 88 active ingredients and 209 products.」

「As part of its efforts to expand the product lineup, the Company newly launched 3 generic drug active ingredients and 5 products in December 2021. As of the end of December 2021, generic drug products for sale totaled 88 active ingredients and 209 products.」

「In the pharmaceutical manufacturing and sales business, the Company further strengthened initiatives for product quality control, including the introduction of the latest quality-control and analytical equipment. As part of its efforts to expand the product lineup, it newly launched 1 generic drug active ingredient and 2 products in August and obtained marketing approval for 1 active ingredient and 1 product. As of the end of September 2021, generic drug products for sale totaled 85 active ingredients and 204 products.」

「In addition, we expanded the generic medicine product lineup, including by newly launching 3 ingredients and 6 products in the supplementary drug price listing in June this year. As of the end of June 2021, generic medicines on sale totaled 85 ingredients and 202 products.」

「In addition, we expanded the generic medicine product lineup, including by newly launching 2 ingredients and 7 products in December 2020. As of the end of December 2020, products on sale totaled 83 ingredients and 202 products.」

「In the pharmaceutical manufacturing and sales business, the Company newly launched 1 active ingredient and 3 products in July and obtained marketing approval for 2 active ingredients and 7 products in August, while working to expand its product lineup and ensure a stable supply of high-quality, high-value-added generic drugs. As of the end of September 2020, generic drug products for sale totaled 81 active ingredients and 195 products.」

「In the pharmaceutical manufacturing and sales business, the Company newly launched 7 generic drug active ingredients and 22 products in June’s supplemental National Health Insurance drug price listing and worked to expand its product lineup while ensuring a stable supply of high-quality, high-value-added generic drugs. As of the end of June 2020, generic drug products for sale totaled 81 active ingredients and 192 products.」

「During the fiscal year, the Company newly launched 3 active ingredients and 8 products and obtained marketing approval for 3 active ingredients and 8 products in February 2020, continuing to expand its product lineup. At the end of the fiscal year, it handled 76 active ingredients and 164 generic drug products.」

「For Kyosai Mirai Pharma products, the Company continued to work on expanding the product lineup while ensuring a stable supply of high-quality, high-value-added generic drugs, including the launch of 1 active ingredient and 2 products in December 2019. As of the end of December 2019, products for sale totaled 76 active ingredients and 164 products.」

「For Kyosai Mirai Pharma products, the Company continued to work on expanding the product lineup while ensuring a stable supply of high-quality, high-value-added generic drugs, including the launch of 1 active ingredient and 4 products in June and 1 active ingredient and 2 products in September. As of the end of September 2019, products for sale totaled 75 active ingredients and 162 products.」

「For Kyosai Mirai Pharma products, the Company is working to expand the product lineup while ensuring a stable supply of high-quality, high-value-added generic drugs, including the launch of 1 active ingredient and 4 products in June’s supplemental National Health Insurance drug price listing. As of the end of June 2019, products for sale totaled 74 active ingredients and 160 products.」

「As one business strategy for improving profitability over the medium to long term, Kyosai Mirai Pharma Co., Ltd., launched in November 2016, expanded its lineup by accepting the transfer of generic drugs for which Fujifilm Pharma Co., Ltd. had been the marketing authorization holder or distributor. As of the end of March 2019, it handled 73 active ingredients and 156 generic drug products.」

「Kyosai Mirai Pharma Co., Ltd. continued to work on the stable supply of high-quality, high-value-added generic drugs and the expansion of its product lineup, bringing products for sale to 62 active ingredients and 128 products as of 1 February 2019. From 1 October 2018, prescription pharmaceuticals comprising 26 active ingredients for which Fujifilm Pharma Co., Ltd. was the marketing authorization holder and prescription pharmaceuticals comprising 30 active ingredients for which it was the distributor have been transferred, with the marketing authorization and sales changed from Fujifilm Pharma Co., Ltd. to Kyosai Mirai Pharma Co., Ltd. in stages. The transfer of all products is scheduled to be completed by 1 April 2019.」

「Kyosai Mirai Pharma Co., Ltd., launched with a view to achieving an 80% volume share for generic drugs, continued to work on the stable supply of high-quality, high-value-added generic drugs and the expansion of its product lineup. As of the end of October 2018, products for sale totaled 34 active ingredients and 74 products. From 1 October, prescription pharmaceuticals comprising 26 active ingredients for which Fujifilm Pharma Co., Ltd. was the marketing authorization holder and prescription pharmaceuticals comprising 30 active ingredients for which it was the distributor have been transferred, with the marketing authorization and sales changed from Fujifilm Pharma Co., Ltd. to Kyosai Mirai Pharma Co., Ltd. in stages. The transfer of all products is scheduled to be completed by 1 April 2019.」

「As of the end of June 2018, products for sale totaled 15 active ingredients and 42 products.」

「Kyosai Mirai Pharma Co., Ltd., launched in November 2016, has promoted the stable supply of high-quality, high-value-added generic drugs, and as of March 2018, its products for sale totaled 14 active ingredients and 40 products.」

「Kyosai Mirai Pharma Co., Ltd., launched in November 2016, continued its proactive initiatives, including the launch in December of 6 active ingredients and 14 products, including 4 active ingredients and 9 products for which the “Kyosai Mirai Pharma” brand obtained marketing approval for the first time.」

「Kyoso Mirai Pharma Co., Ltd., established last November in preparation for the era when generics account for 80% of volume, obtained its first marketing authorization under the Kyoso Mirai Pharma brand in August for 6 ingredients and 15 products. In September, it newly launched 2 ingredients and 5 products, bringing the number of products launched to 6 ingredients and 19 products.」

「Kyosai Mirai Pharma Co., Ltd., launched in November last year, newly launched 2 active ingredients and 11 products in June’s supplemental National Health Insurance drug price listing, bringing the “Kyosai Mirai Pharma” brand’s products to 4 active ingredients and 14 products.」

「Kyosai Mirai Pharma Co., Ltd., launched in November 2016, made a successful start in both sales and profit by launching 2 active ingredients and 3 products in December’s supplemental National Health Insurance drug price listing. It will continue to establish an integrated manufacturing and sales business model that accurately meets customer demand and aims to provide prescription pharmaceuticals, centered on high-quality, high-value-added generic drugs, in a stable and rational manner.」

「Kyosai Mirai Pharma Co., Ltd., launched on 1 November last year, made a successful start by launching 2 active ingredients and 3 products in December following their supplemental listing. It will continue to establish an integrated manufacturing and sales business model that accurately meets customer demand and aims to provide prescription pharmaceuticals, centered on high-quality, high-value-added generic drugs, in a stable and rational manner.」

「In addition, Kyosai Mirai Pharma Co., Ltd. was launched on 1 November and began working on pharmaceutical development, manufacturing and sales, in addition to contract manufacturing. By making maximum use of the Company’s management resources, it aims to establish an integrated manufacturing and sales business model that accurately meets customer demand and to provide prescription pharmaceuticals, centered on high-quality, high-value-added generic drugs, in a stable and rational manner.」